FDA Approves Mylan’s Humira Biosimilar
Hulio Version Of Adalimumab Will Have To Wait Three Years To Launch
Mylan’s Hulio has become the sixth biosimilar version of Humira to be approved by the US FDA. However, all of these adalimumab biosimilars face a wait until 2023 before they can enter the market.
